Benzinga | Nov 4, 2021 10:00AM EDT

Oppenheimer Maintains Perform on Aurinia Pharmaceuticals, Raises Price Target to $33

Oppenheimer analyst Justin Kim maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Perform and raises the price target from $32 to $33.